A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial

[1]  A. García-Sastre,et al.  Activity of human serum antibodies in an influenza virus hemagglutinin stalk-based ADCC reporter assay correlates with activity in a CD107a degranulation assay. , 2020, Vaccine.

[2]  L. Brammer,et al.  Early Season Pediatric Influenza B/Victoria Virus Infections Associated with a Recently Emerged Virus Subclade — Louisiana, 2019 , 2020, MMWR. Morbidity and mortality weekly report.

[3]  A. Clayton,et al.  Targeting Antigen to the Surface of EVs Improves the In Vivo Immunogenicity of Human and Non-human Adenoviral Vaccines in Mice , 2019, Molecular therapy. Methods & clinical development.

[4]  Gavin J. D. Smith,et al.  Divergent evolutionary trajectories of influenza B viruses underlie their contemporaneous epidemic activity , 2019, Proceedings of the National Academy of Sciences.

[5]  R. Albrecht,et al.  Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohorts , 2019, npj Vaccines.

[6]  D. Skowronski,et al.  Paradoxical clade- and age-specific vaccine effectiveness during the 2018/19 influenza A(H3N2) epidemic in Canada: potential imprint-regulated effect of vaccine (I-REV) , 2019, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[7]  Manish M Patel,et al.  Spread of antigenically drifted influenza A(H3N2) viruses and vaccine effectiveness in the United States during the 2018-2019 season. , 2019, The Journal of infectious diseases.

[8]  I. Wilson,et al.  Broadly protective human antibodies that target the active site of influenza virus neuraminidase , 2019, Science.

[9]  Christopher T. Stamper,et al.  Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial , 2019, The Lancet. Infectious diseases.

[10]  R. Albrecht,et al.  Vaccination With Viral Vectors Expressing Chimeric Hemagglutinin, NP and M1 Antigens Protects Ferrets Against Influenza Virus Challenge , 2019, Front. Immunol..

[11]  F. Krammer.  The human antibody response to influenza A virus infection and vaccination , 2019, Nature Reviews Immunology.

[12]  R. Rappuoli,et al.  Safety of AS03-adjuvanted influenza vaccines: A review of the evidence. , 2019, Vaccine.

[13]  I. Wilson,et al.  A Site of Vulnerability on the Influenza Virus Hemagglutinin Head Domain Trimer Interface , 2019, Cell.

[14]  T. Kepler,et al.  Antibodies to a Conserved Influenza Head Interface Epitope Protect by an IgG Subtype-Dependent Mechanism , 2019, Cell.

[15]  L. Gresh,et al.  Novel correlates of protection against pandemic H1N1 influenza A virus infection , 2019, Nature Medicine.

[16]  A. García-Sastre,et al.  Chimeric Hemagglutinin-Based Influenza Virus Vaccines Induce Protective Stalk-Specific Humoral Immunity and Cellular Responses in Mice , 2019, ImmunoHorizons.

[17]  M. Nelson,et al.  Characterization of swine-origin H1N1 canine influenza viruses , 2019, Emerging microbes & infections.

[18]  Zigui Chen,et al.  Frequent Genetic Mismatch between Vaccine Strains and Circulating Seasonal Influenza Viruses, Hong Kong, China, 1996–2012 , 2018, Emerging infectious diseases.

[19]  P. Wilson,et al.  The influenza virus hemagglutinin head evolves faster than the stalk domain , 2018, Scientific Reports.

[20]  F. Krammer,et al.  Broadly protective anti-hemagglutinin stalk antibodies induced by live attenuated influenza vaccine expressing chimeric hemagglutinin. , 2018, Virology.

[21]  P. Palese,et al.  An immuno-assay to quantify influenza virus hemagglutinin with correctly folded stalk domains in vaccine preparations , 2018, PloS one.

[22]  I. Wilson,et al.  Structural insights into the design of novel anti-influenza therapies , 2018, Nature Structural & Molecular Biology.

[23]  Caitlin E. Mullarkey,et al.  Alveolar macrophages are critical for broadly-reactive antibody-mediated protection against influenza A virus in mice , 2017, Nature Communications.

[24]  P. Palese,et al.  Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for In Vivo Protection in a Serum Transfer Mouse Challenge Model , 2017, mBio.

[25]  R. Albrecht,et al.  A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in preclinical ferret studies , 2017, npj Vaccines.

[26]  Veronika Chromikova,et al.  Generation of a serum free CHO DG44 cell line stably producing a broadly protective anti-influenza virus monoclonal antibody , 2017, PloS one.

[27]  M. Kieny,et al.  Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial , 2017, The Lancet. Infectious diseases.

[28]  M. Eichelberger,et al.  Analysis of Anti-Influenza Virus Neuraminidase Antibodies in Children, Adults, and the Elderly by ELISA and Enzyme Inhibition: Evidence for Original Antigenic Sin , 2017, mBio.

[29]  Baoshan Zhang,et al.  Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination , 2016, Nature Medicine.

[30]  P. Palese,et al.  A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in mice , 2016, npj Vaccines.

[31]  Michael B. Doud,et al.  Accurate Measurement of the Effects of All Amino-Acid Mutations on Influenza Hemagglutinin , 2016, Viruses.

[32]  P. Palese,et al.  Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in Humans , 2016, mBio.

[33]  M. Stukova,et al.  Assessment of immune responses to H5N1 inactivated influenza vaccine among individuals previously primed with H5N2 live attenuated influenza vaccine , 2015, Human vaccines & immunotherapeutics.

[34]  Adrian Apetri,et al.  A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen , 2015, Science.

[35]  P. Palese,et al.  Advances in the development of influenza virus vaccines , 2015, Nature Reviews Drug Discovery.

[36]  R. Hai,et al.  Induction of Broadly Reactive Anti-Hemagglutinin Stalk Antibodies by an H5N1 Vaccine in Humans , 2014, Journal of Virology.

[37]  Carl W Davis,et al.  Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans , 2014, Proceedings of the National Academy of Sciences.

[38]  R. Karron,et al.  A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response. , 2014, The Journal of infectious diseases.

[39]  P. Palese,et al.  Broadly neutralizing hemagglutinin stalk–specific antibodies require FcγR interactions for protection against influenza virus in vivo , 2014, Nature Medicine.

[40]  Antoine M. van Oijen,et al.  Mechanisms of Hemagglutinin Targeted Influenza Virus Neutralization , 2013, PloS one.

[41]  R. Hai,et al.  H3 Stalk-Based Chimeric Hemagglutinin Influenza Virus Constructs Protect Mice from H7N9 Challenge , 2013, Journal of Virology.

[42]  Rong Hai,et al.  Genome-wide mutagenesis of influenza virus reveals unique plasticity of the hemagglutinin and NS1 proteins , 2013, Proceedings of the National Academy of Sciences.

[43]  P. Palese,et al.  Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system. , 2013, Journal of visualized experiments : JoVE.

[44]  James E. Crowe,et al.  Antibody Recognition of the Pandemic H1N1 Influenza Virus Hemagglutinin Receptor Binding Site , 2013, Journal of Virology.

[45]  N. Heaton,et al.  Hemagglutinin Stalk-Based Universal Vaccine Constructs Protect against Group 2 Influenza A Viruses , 2013, Journal of Virology.

[46]  R. Hai,et al.  Chimeric Hemagglutinin Influenza Virus Vaccine Constructs Elicit Broadly Protective Stalk-Specific Antibodies , 2013, Journal of Virology.

[47]  John Steel,et al.  Cross-neutralization of influenza A viruses mediated by a single antibody loop , 2012, Nature.

[48]  N. S. Laursen,et al.  Highly Conserved Protective Epitopes on Influenza B Viruses , 2012, Science.

[49]  R. Albrecht,et al.  Influenza Viruses Expressing Chimeric Hemagglutinins: Globular Head and Stalk Domains Derived from Different Subtypes , 2012, Journal of Virology.

[50]  J. Skehel,et al.  A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins , 2011, Science.

[51]  J. Yewdell,et al.  MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza Vaccines , 2011, Science Translational Medicine.

[52]  W. C. Hwang,et al.  Wide Prevalence of Heterosubtypic Broadly Neutralizing Human Anti–Influenza A Antibodies , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[53]  N. Cox,et al.  Genetic bases of the temperature-sensitive phenotype of a master donor virus used in live attenuated influenza vaccines: A/Leningrad/134/17/57 (H2N2). , 2011, Virology.

[54]  A. García-Sastre,et al.  Generation of recombinant influenza virus from plasmid DNA. , 2010, Journal of visualized experiments : JoVE.

[55]  Gira Bhabha,et al.  Antibody Recognition of a Highly Conserved Influenza Virus Epitope , 2009, Science.

[56]  Boguslaw Stec,et al.  Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses , 2009, Nature Structural &Molecular Biology.

[57]  A. Bousvaros,et al.  Immune Response to Influenza Vaccine in Children With Inflammatory Bowel Disease , 2009, The American Journal of Gastroenterology.

[58]  F. Hayden,et al.  Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. , 2007, JAMA.

[59]  P. Palese,et al.  Influenza: old and new threats , 2004, Nature Medicine.

[60]  Y. Isegawa,et al.  A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains , 1993, Journal of virology.

[61]  A. S. Beare,et al.  The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses , 1972, Epidemiology and Infection.

[62]  Yongchao Ge,et al.  Localized mucosal response to intranasal live attenuated influenza vaccine in adults. , 2013, The Journal of infectious diseases.